Miyamoto A, Kanai T, Monden M, Sakon M, Gotoh M, Umeshita K, Hasuike Y, Nakano H, Takiguchi S, Yokoyama S
Dept. of Surgery II, Osaka University Medical School.
Gan To Kagaku Ryoho. 1993 Aug;20(11):1465-8.
The efficacy of transarterial immuno-embolization therapy (TIE) was examined in six operable patients with hepatocellular carcinoma (HCC). We administered OK-432, fibrinogen (30 mg/ml) and thrombin (1 U/ml) through a catheter which was inserted into the tumor-feeding artery. In all patients with a high level of tumor markers (AFP and PIVKA-II), the level decreased promptly to less than the pretreatment level after TIE therapy. The therapy has not caused any serious side effects. No disturbance of the coagulation-fibrinolysis system due to TIE was observed in any patient. Histological examination of resected specimens following TIE showed massive infiltration of mononuclear cells around tumor cell nests, and lytic necrosis as well as coagulation necrosis of the main tumor and the intrahepatic metastases. Our results indicate that TIE may be an effective and promising modality for HCC patients.
对6例可手术切除的肝细胞癌（HCC）患者进行了经动脉免疫栓塞治疗（TIE）疗效研究。通过插入肿瘤供血动脉的导管给予OK-432、纤维蛋白原（30mg/ml）和凝血酶（1U/ml）。所有肿瘤标志物（甲胎蛋白和异常凝血酶原-II）水平较高的患者，经TIE治疗后其水平迅速降至治疗前水平以下。该治疗未引起任何严重副作用。未观察到任何患者因TIE导致凝血-纤溶系统紊乱。TIE术后切除标本的组织学检查显示，肿瘤细胞巢周围有大量单核细胞浸润，主要肿瘤及肝内转移灶出现溶解性坏死和凝固性坏死。我们的结果表明，TIE可能是一种对HCC患者有效且有前景的治疗方式。
